UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 20, 2025
Rocket Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-36829
|
04-3475813
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Registrant’s telephone number, including area code: (646) 440-9100
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common stock, $0.01 par value
|
|
RCKT
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
|
On August 20, 2025, Aaron Ondrey resigned as Chief Financial Officer of Rocket Pharmaceuticals, Inc. (the “Company”), effective September 5, 2025, to pursue other
opportunities.
On August 25, 2025, Martin Wilson, the Company’s General Counsel and Chief Corporate Officer and the Company’s Corporate Secretary, was appointed as the Company’s interim
Principal Financial Officer, effective September 8, 2025.
Mr. Wilson, age 48, joined the Company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024. Mr. Wilson has
nearly 20 years of legal, compliance and executive experience and accomplishment within the life sciences industry. Before joining the Company, Mr. Wilson was General Counsel and Chief Corporate Officer at Ichnos Sciences Inc. (“Ichnos”), a
research and development company focused on oncology, autoimmune disease and pain management, from January 2020 through November 2021. Prior to his time at Ichnos, Mr. Wilson served as General Counsel at Teligent Inc., a generic pharmaceutical
company, from April 2017 through December 2019. Mr. Wilson earned his Juris Doctorate from Villanova University Charles Widger School of Law.
There is no family relationship between Mr. Wilson and any director, executive officer, or person nominated or chosen by the Company to become a director or executive
officer. In addition, there are no transactions between the Company and Mr. Wilson, or any member of Mr. Wilson’s immediate family, of the type set forth in Item 404(a) of Regulation S-K, other than the compensation received by Mr. Wilson for his
current positions with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
Rocket Pharmaceuticals, Inc.
|
| |
|
|
|
Date: August 25, 2025
|
By:
|
/s/ Martin Wilson
|
| |
|
Martin Wilson
|
| |
|
General Counsel and Chief Corporate Officer, SVP
|
